Latest news with #Pangea
ITV News
26-06-2025
- Health
- ITV News
Thousands of pounds worth of potentially life-threatening tablets seized as part of major operation
In just five months, the police seized 100,000 powerful fake anti-anxiety tablets that can be life-threatening. They are called pregabalin, although on the streets they are known as Belfast buds. The Health Minister, Mike Nesbitt, has described the drug as "widespread in society" and warned that the tablets seized have a "strength of 300mg" but "75mg is the normal dosage". "So even if that is genuine stuff and passes any kind of regulatory test, it's far, far too strong, and it's damaging people's lives up to the point of putting those lives at risk," he said. Hundreds of weight-loss kits, sold on the black market for up to £400, have also also been seized. They were discovered as part of a worldwide operation known as 'Pangea'; the police then carried out follow up searches and interviewed a number of suspects. "You're not just putting money in the pockets of people who are reckless with regard to your health and wellbeing, but also will be using that money to fund other criminal enterprises," warned the Justice Minister. Naomi Long added: "Do not play Russian roulette with your health because that's what you do. You take one of these pills, you do not know what you're taking. "It could be anything from rat droppings to rat poison that's in those tablets, and you're taking that into your body and putting your life at risk. It is not worth the risk." Want a quick and expert briefing on the biggest news stories? Listen to our latest podcasts to find out What You Need To Know.
Yahoo
05-06-2025
- General
- Yahoo
Zion museum's new temporary exhibit delves into research on end-Triassic extinction
SPRINGDALE, Utah () — A new, temporary exhibit featuring research on the Triassic and Jurassic periods is available at the Zion Human History Museum. It features research on geoscience and extinction, as well as a model phytosaur skull. The new exhibit will bring guests through the late Triassic period, the end-Triassic Extinction, and the beginnings of the Jurassic period, between 227 to 180 million years ago. This is the culmination of a seven-year research project involving scientists from all over. Dr. Celina Suarez, a geoscience professor at the University of Arkansas, led the team. The rocks at Zion National Park were key to this research, as they were used to study and understand the climate change that led to the end-Triassic Extinction. Two Utah campgrounds included in list of 50 Favorite Places to Camp in America Right Now: Hipcamp According to a press release from Zion National Park, Dr. Suarez and her team identified 'a spike in CO2 levels in the park's Moenave Formation.' Using this information, the scientists were able to pinpoint a rapid increase in volcanic eruptions that led to the supercontinent Pangea splitting. 'We've got to look at the geologic past and all these past events to understand where we're going in the future,' Dr. Suarez is quoted in a press release. 'If we can just get one or two people that come and visit Zion to understand that … I've done my job.' Alongside that discovery, which is mirrored in sites all around the world, Dr. Suarez and the team of scientists found that the CO2 spike would also cause wildfires and 'intense weather patterns' that led to the End Triassic Extinction, which wiped out 'approximately 80 percent of all marine and terrestrial species on Earth,' according to the release. 10 hikes with stunning wildflowers across Utah The new exhibit at the Zion History Museum was built on this research, and was created by a collaboration between scientists, artists, and partners. Zion National Park extends a special thanks to the Zion Forever Project, St. George Dinosaur Discovery Museum, the Utah Geological Survey and the National Science Foundation in their release. 'None of us could have done anything to this scale by ourselves,' Robyn Henderek, the park's physical scientist, is quoted. 'We all had a role to play in this process.' For more information about visiting this new exhibit, visit . Orangutan at Utah's Hogle Zoo expecting baby this month Trump and Musk feud escalates Tariff battle continues Zion museum's new temporary exhibit delves into research on end-Triassic extinction One person dead following accident on Highway 89 near Utah-Sanpete county line Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
04-06-2025
- Business
- Yahoo
Pangea Named to Rising in Cyber 2025 List of Top Cybersecurity Startups
Selected by over 150 CISOs, recipients representing the most innovative cybersecurity startups to be recognized on NYSE trading floor tonight PALO ALTO, Calif., June 4, 2025 /PRNewswire/ -- Pangea, a leading provider of AI security guardrails, today announced its inclusion in Rising in Cyber 2025, launched by Notable Capital to spotlight the 30 most promising cybersecurity startups shaping the future of security. Unlike traditional rankings, Rising in Cyber 2025 honorees were selected through a multi-stage process grounded in real-world validation. Leading cybersecurity venture firms submitted nominations, and nearly 150 Chief Information Security Officers (CISOs) and senior security executives voted on the final list, highlighting the companies solving the most urgent challenges facing today's security teams. Pangea was selected for delivering the industry's most comprehensive AI guardrails, enabling organizations to secure employee AI use and ship secure AI applications faster. The company's AI Guardrail Platform delivers measurable value to security teams navigating today's complex threat landscape. The company joins a cohort that has collectively raised over $7.8 billion according to Pitchbook as of May 2025, and is defining the next era of cybersecurity across key areas like identity, application security, agentic AI, and security operations. "The demand for cybersecurity innovation has never been greater. As the underlying technologies evolve and agentic AI reshapes everything from threat detection to team workflows, we're witnessing a shift from reactive defense to proactive, intelligence-driven operations," said Oren Yunger, Managing Partner at Notable Capital. "What makes this list special is that it reflects real-world validation—honorees were chosen by CISOs who face these challenges every day. Congratulations to this year's Rising in Cyber companies for building the solutions that modern security leaders truly want and need." In celebration, honorees will be recognized today at the New York Stock Exchange (NYSE) alongside top security leaders and investors. "We are thrilled to receive this recognition from Notable Capital and its esteemed community of security leaders," said Oliver Friedrichs, Co-founder & CEO of Pangea. "This validates Pangea's commitment to pioneering the AI security market through continuous innovation. As AI continues to create new attack vectors and vulnerabilities, we remain dedicated to staying at the forefront, safeguarding our clients' digital assets while driving industry-wide transformation." Pangea's recognition follows new AI security product launches earlier this year designed to help customers defend against threats like prompt injection and sensitive information disclosure to large language models. Pangea serves a wide range of customers, from Fortune 100 companies to AI-native technology startups. To learn more about Rising in Cyber 2025, visit About PangeaPangea's AI Guardrail Platform empowers security teams to ship secure AI applications quickly and protect workforce AI use with the industry's most comprehensive set of AI guardrails, easily deployed via gateways or into applications with just a few lines of code. Pangea stops LLM security threats ranging from prompt injection to sensitive data leakage, covering 8 out of 10 OWASP Top Ten Risks for LLM apps, while accelerating engineering velocity and unlocking AI runtime visibility and control for security teams. For more information, visit or contact: press@ Media Contact: Growth Stack Media | 415-574-0738 View original content to download multimedia: SOURCE Pangea Cyber
Time Out
29-05-2025
- Entertainment
- Time Out
Mendoza sounds: 11 must-listen bands from Mendoza
This band offers songs blending Soul, Jazz, Funk, Rock, and Hip-Hop elements, with touches of Latin sounds. They started making waves in the underground scene in 2010, evolving with natural musical maturation and sound experimentation. Their first album with the stable lineup—Nawel 'Chino' Lim, Tomás Lazzaro, Francisca Figueroa, Ricardo 'Tapa' Quirós, and Quito Pithod—came out in 2015. Their catalog includes the self-titled Spaghetti Western and Pangea, plus singles like 'Tiembla,' 'Ir y venir,' and 'Mansa buena onda,' which explore reflection, empowerment, and celebration of Latin roots. Their latest releases 'La Cobarde' and 'Yarará' mark a new musical era. Fun fact: They recently kicked off a national tour with fellow Mendoza band Pasado Verde, promising nights full of dancing and excitement. In Buenos Aires, they will play at Niceto Club on 05/28 and Auditorio Oeste on 05/30.
Yahoo
16-05-2025
- Business
- Yahoo
SYK Q1 Earnings Call: Stryker Delivers Revenue Beat, Cites International Growth and Tariff Headwinds
Medical technology company Stryker (NYSE:SYK) announced better-than-expected revenue in Q1 CY2025, with sales up 11.9% year on year to $5.87 billion. Its non-GAAP profit of $2.84 per share was 4% above analysts' consensus estimates. Is now the time to buy SYK? Find out in our full research report (it's free). Revenue: $5.87 billion vs analyst estimates of $5.68 billion (11.9% year-on-year growth, 3.2% beat) Adjusted EPS: $2.84 vs analyst estimates of $2.73 (4% beat) Adjusted EBITDA: $1.45 billion vs analyst estimates of $1.42 billion (24.7% margin, 2% beat) Adjusted EPS guidance for the full year is $13.33 at the midpoint, missing analyst estimates by 1% Operating Margin: 14.3%, down from 18.5% in the same quarter last year Free Cash Flow Margin: 2.2%, up from 0.7% in the same quarter last year Organic Revenue rose 10.1% year on year, in line with the same quarter last year Market Capitalization: $149.9 billion Stryker's first quarter results reflected healthy demand across both its MedSurg & Neurotechnology and Orthopaedics divisions, with management highlighting double-digit growth in its U.S. trauma, extremities, neurocranial, and surgical technologies segments. CEO Kevin Lobo emphasized the outperformance of new product platforms, especially the Mako robotic system and Pangea trauma plating system, as key contributors to market share gains. Management also pointed to continued strength in international markets, particularly Australia, New Zealand, Japan, and Europe, as a foundation for ongoing growth. Looking ahead, Stryker's 2025 guidance reflects the company's expectation for continued high-single-digit organic sales growth, while acknowledging several headwinds. CFO Preston Wells noted that tariffs—estimated to impact costs by $200 million this year—will require ongoing mitigation through pricing, supply chain optimization, and disciplined spending. Management cited strong order backlogs and robust demand for capital equipment as supportive factors, but recognized supply chain disruptions in the medical business and the need to integrate recent acquisitions like Inari Medical as considerations for the remainder of the year. Stryker's management attributed the quarter's performance to broad-based demand, new product uptake, and successful execution in core and emerging markets. The following insights summarize the major drivers behind the company's recent financial results: Robotic Surgery Momentum: The Mako robotic platform set a Q1 record for installations, with high utilization rates globally. Management expects continued growth in hips and knees as Mako expands into new indications and geographies. Product Innovation Pipeline: Recent launches, such as the LIFEPAK 35 defibrillator and the Pangea trauma plating system, drove meaningful sales growth. LIFEPAK 35 is set to expand into Europe and Japan, while Pangea will enter Australia and Canada this year and Japan in 2026. International Expansion: Stryker underscored strong growth in Australia, New Zealand, Japan, and Europe, citing these markets as significant future catalysts. The company expects regulatory delays to cause a lag between U.S. and international product uptake, but sees a multi-year runway for international sales. M&A and Portfolio Optimization: The acquisition of Inari Medical was completed, integrating into the vascular division. Stryker also finalized the sale of its U.S. Spinal Implants business, sharpening its strategic focus and capital allocation. Capital Equipment Demand: Management reported double-digit growth across capital businesses and stated that hospital capital spending remains robust, with a healthy order backlog and no current signs of a slowdown. Management expects Stryker's growth to be shaped by ongoing product launches, international expansion, and efforts to offset tariff-related cost pressures. The company's outlook is rooted in strong procedural demand, but it faces operational and macroeconomic uncertainties. Tariff Mitigation Efforts: Stryker plans to counteract the estimated $200 million tariff impact through pricing strategies, expense discipline, and supply chain optimizations. CFO Preston Wells noted that gross and operating margin improvement will depend on successfully executing these measures. Capital Equipment Backlog: The elevated order book for capital equipment is expected to support sales growth through the year, with management citing a six-month visibility into demand. Integration of Acquisitions and Divestitures: The performance of newly acquired Inari Medical and the transition of the U.S. Spinal Implants business out of the portfolio are expected to influence both revenue growth and margin profiles in coming quarters. Marcus Robert (JPMorgan): Pressed on how Stryker will absorb the $200 million tariff impact and what mitigation levers are most effective. Management cited sales momentum, pricing, and discretionary spending as key tools. Larry Biegelsen (Wells Fargo): Asked about the sustainability of operating margin expansion despite tariffs, with Preston Wells clarifying that margin gains will come from both gross margin and operating expense initiatives. Joanne Wuensch (Citi): Inquired about the ongoing integration of Inari Medical and whether there were any surprises post-acquisition. Management reported favorable early results and cultural alignment. Ryan Zimmerman (BTIG): Sought details on the international hip business's growth durability, with CEO Kevin Lobo attributing strong results to recent acquisitions and pending product launches in Europe and Asia-Pacific. Travis Steed (Bank of America): Questioned the details and geographic exposure of the tariff impact, as well as mitigation strategies for 2026. Management said future plans remain flexible due to the changing environment. In the coming quarters, the StockStory team will closely monitor (1) the rollout and adoption pace of new products such as Mako 4 and LIFEPAK 35 in both U.S. and international markets, (2) Stryker's ability to offset tariff-related cost pressures through pricing and operational efficiency, and (3) ongoing strength in capital equipment demand and procedural volumes globally. Additionally, we will watch for integration milestones with Inari Medical and any updates regarding regulatory changes or supply chain disruptions. Stryker currently trades at a forward P/E ratio of 28.4×. At this valuation, is it a buy or sell post earnings? Find out in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
